Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

(2020) Alba Grifoni et al.   CELL

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

(2020) Kristi Williams et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

(2020) Till Koch et al.   LANCET INFECTIOUS DISEASES

A serological assay to detect SARS-CoV-2 seroconversion in humans

(2020) Fatima Amanat et al.   NATURE MEDICINE

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

(2020) Abishek Chandrashekar et al.   SCIENCE

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

(2020) Jingyou Yu et al.   SCIENCE

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

(2020) Caroline Atyeo et al.   IMMUNITY

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

(2020) Noe B. Mercado et al.   NATURE

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

(2020) Davide F. Robbiani et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury

(2020) Matija Fenrich et al.   Frontiers in Cellular Neuroscience

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

(2020) Takuya Sekine et al.   CELL

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

(2020) Carolyn Rydyznski Moderbacher et al.   CELL

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

(2020) Ugur Sahin et al.   NATURE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acellular Pertussis Vaccines Induce Anti-pertactin Bactericidal Antibodies Which Drives the Emergence of Pertactin-Negative Strains

(2020) Elodie Lesne et al.   Frontiers in Microbiology

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

(2020) Katie J. Ewer et al.   NATURE MEDICINE

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania

(2019) Zacchaeus Anywaine et al.   JOURNAL OF INFECTIOUS DISEASES

A versatile high throughput assay to characterize antibody-mediated neutrophil phagocytosis

(2019) Christina B. Karsten et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

(2018) Dan H Barouch et al.   LANCET

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial

(2018) Emil C Reisinger et al.   LANCET

Chimpanzee Adenovirus Vector Ebola Vaccine

(2017) Julie E. Ledgerwood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Jing-Xin Li et al.   Lancet Global Health

Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines

(2014) Jean-Louis Excler et al.   Clinical and Vaccine Immunology

Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy

(2014) Liat Binyamin et al.   JOURNAL OF IMMUNOLOGY

Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial

(2014) Susanne H Hodgson et al.   MOLECULAR THERAPY

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

(2014) David J DiLillo et al.   NATURE MEDICINE

Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure

(2014) Sumi Biswas et al.   PLoS One

Cellular immune correlates of protection against symptomatic pandemic influenza

(2013) Saranya Sridhar et al.   NATURE MEDICINE

High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples

(2012) Eric P. Brown et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

(2012) Tom M Wilkinson et al.   NATURE MEDICINE

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

(2012) Matthew D. J. Dicks et al.   PLoS One

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

(2010) Margaret E. Ackerman et al.   JOURNAL OF IMMUNOLOGICAL METHODS

T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice

(2010) J. Zhao et al.   JOURNAL OF VIROLOGY

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET